Dr. Agarwal's Health Care Limited, a prominent player in the healthcare sector, has announced a significant change in its statutory auditors. The company's Board of Directors has approved the appointment of S.R. Batliboi & Associates LLP as the new statutory auditors, replacing Deloitte Haskins & Sells.

Key Highlights of the Auditor Change

• Resignation of Current Auditors: Deloitte Haskins & Sells has stepped down as the statutory auditors of Dr. Agarwal's Health Care Limited and its material subsidiary, Dr. Thind Eye Care Private Limited, effective November 12, 2025.

• Reason for Change: The resignation is part of an effort to align auditors with the company's listed material subsidiary, Dr. Agarwal's Eye Hospital Limited, as part of an ongoing merger process.

• New Auditor Appointment: S.R. Batliboi & Associates LLP has been appointed to fill the casual vacancy, subject to shareholder approval through postal ballot.

• Term of New Auditors: The new auditors will hold office until the conclusion of the 16th Annual General Meeting.

Details of the Auditor Transition

Impact and Implications

The change in auditors is a strategic move aimed at streamlining audit and reporting practices for the combined entity post-merger. Deloitte Haskins & Sells has confirmed that no concerns or issues were raised during their tenure, emphasizing that the transition is purely for operational efficiency.

S.R. Batliboi & Associates LLP, part of the S.R. Batliboi & Affiliates network, brings extensive experience in auditing large listed and private companies across diverse market segments. Their appointment is expected to provide continuity and expertise in financial reporting as Dr. Agarwal's Health Care Limited moves forward with its corporate restructuring plans.

Shareholder Approval Process

The appointment of S.R. Batliboi & Associates LLP is subject to shareholder approval, which will be sought through a postal ballot. Shareholders on record as of November 14, 2025, will be eligible to participate in this voting process.

This change in statutory auditors marks a significant corporate action for Dr. Agarwal's Health Care Limited, aligning its audit processes with its strategic objectives and ongoing corporate restructuring efforts.

Dr. Agarwal's Health Care Limited , a leading eye care hospital chain, has reported robust financial performance for the first half of fiscal year 2026, marking significant growth across key metrics.

Financial Highlights

The company achieved a milestone by crossing the INR 1,000 crore revenue mark for the first time in H1 FY26. Here's a breakdown of the key financial metrics:

The company's EBITDA margin improved by 100 basis points to 28.30%, while PAT margin expanded by 270 basis points to 7.20%.

Operational Performance

Dr. Agarwal's Health Care expanded its network significantly during H1 FY26:

• Served over 14.3 lakh patients
• Performed nearly 157,000 surgeries
• Added 24 new Greenfield facilities
• Total network reached 258 facilities across 239 locations in India

The company's presence is now well-diversified with 31% of facilities in Tier 1 cities, 62% in other cities, and 7% located internationally.

Surgical Advancements

The company reported strong growth in specialized surgical procedures:

• High-end cataract surgeries increased by 41.70% year-on-year
• Robotic cataract surgeries grew by 69.00%
• Lenticular procedures (SMILE surgeries) increased by 11.50%
• Retinal surgeries rose by 23.00%

Regional Performance

• Southern Region: Contributed 64% of total group revenues, growing by 22.20% year-on-year to INR 635.00 crores
• Western Region: Contributed 15.20% of overall group revenues, growing by 16.60% to INR 150.00 crores
• Northern Region: Contributed 7.30% of group revenues, growing by 14.20% to INR 72.00 crores

Future Outlook

The company plans to launch 30 more facilities in the remaining quarters of FY26, with a focus on expanding its presence in Delhi-NCR and other key markets.

Dr. Adil Agarwal, CEO of Dr. Agarwal's Health Care Limited, commented, "Our continued emphasis on operational efficiencies and disciplined execution has enabled us to close the first half on a strong note despite the impact of festivities and unexpected rainfalls across parts of India."

The company remains optimistic about its growth trajectory, expecting H2 to be stronger than H1, driven by its expansion plans and focus on advanced surgical procedures.